SRT2104

SRT2104, also known as GSK2245840, is a novel, first-in-class, highly selective small molecule activator of the NAD + dependent deacetylase SIRT1. SRT2104 has been developed as a selective small molecule activator of SIRT1, a NAD (+) -dependent deacetylase involved in the regulation of energy homeostasis and the modulation of various metabolic pathways, including glucose metabolism, oxidative stress and lipid metabolism. SIRT1 has been suggested as putative therapeutic target in multiple age-related diseases including type 2 diabetes and dyslipidemias. (In Vivo) :SRT 2104 (100 mg/kg/day, supplemented in diet for 24 weeks) increases SIRT1 protein without altering Sirt1 mRNA in diabetic mice.SRT 2104 (100 mg/kg/day, supplemented in diet for 24 weeks) decreases testicular oxidative stress, activation of apoptotic signaling, and ER stress in diabetic mice.SRT 2104 (0.5%; for 18 weeks) improves motor function and increases survival in N171-82Q HD mice.